Literature DB >> 12458390

Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.

Matthias Schmidt1, Eva Fischer, Markus Dietlein, Olaf Michel, Kerstin Weber, Detlef Moka, Eberhard Stennert, Harald Schicha.   

Abstract

Paragangliomas or glomus tumours of the head and neck region are rare somatostatin receptor-expressing neuroendocrine tumours. Precise preoperative diagnosis is of special importance in order to adequately weigh the potential benefit of the operation against the inherent risks of the procedure. In this study, the clinical value of somatostatin receptor imaging was assessed in 19 patients who underwent somatostatin receptor scintigraphy because of known or suspected paraganglioma of the head and neck region. The results were compared with the results of computed tomography and/or magnetic resonance imaging, histology and clinical follow-up. [(111)In-DTPA- D-Phe(1)]-octreotide scintigraphy was performed 4-6 and 24 h after i.v. injection of 140-220 MBq (111)In-octreotide. Whole-body and planar images as well as single-photon emission tomography images were acquired and lesions were graded according to qualitative tracer uptake. Somatostatin receptor imaging was positive in nine patients, identifying paragangliomas for the first time in three patients and recurrent disease in six patients. In one patient, a second, previously unknown paraganglioma site was identified. Negative results were obtained in ten patients. These patients included one suffering from chronic hyperplastic otitis externa, one with granuloma tissue and an organised haematoma, one with an acoustic neuroma, one with an asymmetric internal carotid artery, two with ectasia of the bulbus venae jugularis and one with a jugular vein thrombosis. In two patients with a strong family history of paraganglioma, individual involvement could be excluded. In only one patient did somatostatin receptor imaging and magnetic resonance imaging yield false negative results in respect of recurrent paraganglioma tissue. It is concluded that somatostatin receptor scintigraphy provides important information in patients with suspected paragangliomas of the head and neck region and has a strong impact on further therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458390     DOI: 10.1007/s00259-002-0939-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  14 in total

Review 1.  The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review.

Authors:  Juan P Brito; Noor Asi; Michael R Gionfriddo; Catalina Norman; Aaron L Leppin; Claudia Zeballos-Palacios; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2015-02-06       Impact factor: 3.633

Review 2.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

Review 3.  Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.

Authors:  H J L M Timmers; D Taieb; K Pacak
Journal:  Horm Metab Res       Date:  2012-03-07       Impact factor: 2.936

Review 4.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 5.  Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.

Authors:  David Taïeb; Arthur Varoquaux; Clara C Chen; Karel Pacak
Journal:  Semin Nucl Med       Date:  2013-11       Impact factor: 4.446

Review 6.  Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.

Authors:  R J Hicks
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909

7.  Familial cervical paragangliomas with lymph node metastasis expressing somatostatin receptor type 2A.

Authors:  Noriko Kimura; Hiroo Tateno; Shigeru Saijo; Akira Horii
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

Review 8.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

9.  Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.

Authors:  M Pulcrano; L Camera; L Pagano; S Del Vecchio; D Ferone; L Bodei; A Murgia; L Pace; G Storto; G Paganelli; A Colao; M Salvatore; G Lombardi; B Biondi
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

10.  EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.